Targeting ALYREF oncogenic protein for the treatment of neuroblastoma

Back to search results
PROJECT DESCRIPTION

MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. We have identified ALYREF as a novel regulator of MYCN function and found that ALYREF-mediated stabilization of MYCN protein contributes to the development of neuroblastoma. Our findings demonstrated a critical role for ALYREF as cofactor in MYCN-driven neuroblastoma and highlighted competitive inhibition of the ALYREF-MYCN protein binding as a novel therapeutic strategy in the disease. The PhD project will focus on developing selective and potent ALYREF inhibitors for the treatment of neuroblastoma using a range of in vitro and in vivo models.

IDEAL CANDIDATE

The candidates must demonstrate a strong commitment to their PhD studies, conduct high quality of medical research, willing to develop their careers and to engage with knowledge exchange activities. The candidates need to have strong knowledge in molecular and cellular biology, also have good background knowledge in cancer drug discovery and development. To complete this research project, the candidates will need to have good time management and organisation skills, and have the ability to work independently and also as part of a research team.
Supervisory team
Belamy
Cheung

Medicine
Women's & Children's Health
Zsuzsanna
Nagy

Medicine
Women's & Children's Health
Glenn
Marshall

Medicine
Women's & Children's Health
bcheung@unsw.edu.au